Celastrus Paniculatus vs NSI-189

Mechanism

Seed oil contains sesquiterpenes, alkaloids (celastrine, paniculatin), and polyunsaturated fatty acids that demonstrate dose-dependent cholinergic activity by inhibiting acetylcholinesterase (AChE) and increasing acetylcholine levels in hippocampal and cortical regions. Provides neuroprotection against oxidative stress through elevation of glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Seed extracts attenuate hydrogen peroxide- and glutamate-induced excitotoxic injury in neuronal cells, and exhibit anti-inflammatory and anxiolytic properties.

Standard Dosing

500-1000 mg/day of seed extract (standardized to >8% polyphenols) or 10-15 seeds daily (traditional Ayurvedic dosing, escalated from 1 seed/day)

Timing

Morning, with or without food. Traditional practice involves gradual dose escalation starting from 1 seed daily, increasing by 1 seed per day up to 10-15.

Cycle Duration

Traditionally used in 30-60 day courses. No established cycling protocol from clinical data.

Side Effects

• GI distress
• Nausea (especially at higher doses)
• Diarrhea
• Sedation at high doses

Contraindications

• Pregnancy and lactation (insufficient safety data)
• Known allergy to Celastraceae family plants

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners